CYT — Cyteir Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $111.95m
- -$17.29m
- 44
- 35
- 77
- 51
Annual cashflow statement for Cyteir Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -15 | -20.8 | -42.1 | -46.1 |
| Depreciation | ||||
| Non-Cash Items | -0.568 | 0.467 | 3.46 | 5.39 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -2.16 | 1.47 | 2.15 | -2.53 |
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -17.6 | -18.5 | -36 | -42.5 |
| Capital Expenditures | -0.133 | -0.85 | -1.19 | -0.312 |
| Purchase of Fixed Assets | ||||
| Cash from Investing Activities | -0.133 | -0.85 | -1.19 | -0.312 |
| Net Issuance / Retirement of Stock | ||||
| Cash from Financing Activities | 36.9 | 1.43 | 216 | 0.242 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 19.2 | -18 | 179 | -42.6 |